Tegileridine in postoperative pain: a profile of its use

Declarations
Funding: The preparation of this review was not supported by any external funding
Authorship and conflict of interest: M. B. Brown and Yahiya Y. Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability: Not applicable.

Additional information about this Adis Drug Review can be found here.

Abstract:
Tegileridine (艾苏特)is a novel postoperative analgesic option indicated for moderate-to-severe postoperative pain in China. Tegileridine is a biased μ-opioid receptor agonist with minimal β-arrestin-2 activation relative to morphine and may therefore provide effective analgesia with a lower risk of opioid-related adverse effects such as respiratory depression and gastrointestinal dysfunction. In phase 3 trials, tegileridine significantly reduced pain intensity in adult patients with moderate-to-severe postoperative pain following abdominal or orthopaedic surgeries. Tegileridine was generally well tolerated, with nausea and vomiting being the most common adverse events.

© Springer Nature Switzerland AG 2025